Status:
UNKNOWN
Pharmacodynamic Effects of Ranolazine Versus Amlodipine on Platelet Reactivity
Lead Sponsor:
University of Roma La Sapienza
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
No previous study has assessed the potential of ranolazine to interfere with levels of platelet reactivity in patients with coronary artery disease who are treated with dual antiplatelet therapy. Aim...
Detailed Description
Patients with coronary artery disease (CAD) are often treated with dual antiplatelet therapy (DAT), including aspirin and clopidogrel, to prevent from recurrent atherothrombotic events. Levels of pla...
Eligibility Criteria
Inclusion
- Angiographically-proven coronary artery disease
- Class I indication to dual antiplatelet therapy because of recent (\<12 months) percutaneous coronary intervention and/or recent acute coronary syndrome (\<12 months)
- Stable clinical conditions
- Able to understand and willing to sign the informed consent form
Exclusion
- Use of other drug interfering with CYP activity such as proton pump inhibitors
- Women of child bearing potential patients must demonstrate a negative pregnancy test performed within 24 hours before
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2014
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01490255
Start Date
January 1 2012
End Date
June 1 2014
Last Update
March 26 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
San Raffaele Pisana
Rome, Italy, 00100
2
University La Sapienza
Rome, Italy, 00166